& JOHNSON JOHNSON
CIK 200406 · last filed 2025-12-01
& JOHNSON JOHNSON is a corporate insider who has filed 12 SEC Form 4 insider transactions across 8 companies since 2010. The most recent filing shows the insider sold $127.1K of CVRX on Dec 1, 2025. Across all open-market trades the lifetime net is −$121.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.61B across reported positions. 68 SEC filings were submitted jointly with WILLIAM C WELDON.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.61B
8
12
-$121.83M
Filer Profile
NEW BRUNSWICK, NJ 08933
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CVRX | 10%+ Owner | 4,040,861 | $2.83 | $11.44M | -$1.25M | 3 | 2025-12-01 |
| KVUE | 10%+ Owner | 182,329,550 | $17.75 | $3.24B | $0 | 1 | 2023-08-25 |
| Fusion Pharmaceuticals Inc. (FUSN) Delisted | 10%+ Owner | 2,945,516 | $21.55 | $63.48M | $24.65M | 1 | 2020-07-02 |
| ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | 10%+ Owner | 0 | — | — | -$101.02M | 1 | 2017-11-22 |
| PTGX | 10%+ Owner | 2,449,183 | $145.09 | $355.35M | $14.00M | 1 | 2016-08-18 |
| Neurogene Inc. (AQXP) Delisted | 10%+ Owner | 1,383,366 | — | — | -$68.05M | 3 | 2015-08-12 |
| NERV | 10%+ Owner | 562,520 | $4.12 | $2.32M | $5.85M | 1 | 2015-03-17 |
| TENGION INC (TNGN) Delisted | 10%+ Owner | 119,465 | — | — | $4.00M | 1 | 2010-04-14 |
Recent Filings
12 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-12-01 | CVRX | Sell (S) | −12,674 | -$127.1K | EDGAR |
| 2025-11-25 | CVRX | Sell (S) | −5,400 | -$54.3K | EDGAR |
| 2025-11-10 | CVRX | Sell (S) | −105,064 | -$1.07M | EDGAR |
| 2023-08-25 | KVUE | Other (J) | −1,533,830,450 | $0 | EDGAR |
| 2020-07-02 | Fusion Pharmaceuticals Inc. (FUSN) Delisted | Mixed | +7,341,032 | $24.65M | EDGAR |
| 2017-11-22 | ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | Sell (S) | −36,734,692 | -$101.02M | EDGAR |
| 2016-08-18 | PTGX | Mixed | +4,898,366 | $14.00M | EDGAR |
| 2015-08-12 | Neurogene Inc. (AQXP) Delisted | Sell (S) | −3,029,642 | -$67.89M | EDGAR |
| 2015-03-17 | NERV | Buy (P) | +1,215,806 | $5.85M | EDGAR |
| 2014-12-10 | Neurogene Inc. (AQXP) Delisted | Sell (S) | −16,600 | -$128.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.